Yuhan ends can­cer project with J&J as it signs API deal with Gilead on HIV drugs 

Yuhan and John­son & John­son In­no­v­a­tive Med­i­cine (JJIM), for­mer­ly known as Janssen, end­ed a re­search project af­ter se­cur­ing ap­proval in the US for a sim­i­lar …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER